Shares of MBX Biosciences, Inc. (MBX) have gained 2.6% over the past four weeks to close the last trading session at $17.96, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $59 indicates a potential upside of 228.5%.The average comprises eight short-term price targets ranging from a low of $30.00 to a high of $84.00, with a standard deviation of $17.91. While the lowest estimate ...

Simulations Plus (SLP) closed the last trading session at $18.31, gaining 21.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $23 indicates a 25.6% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $6.48. While the lowest estimate of $16.00 indicates a 12.6% decline from the current price level, the most optimistic analyst exp ...

Shares of First Watch Restaurant Group, Inc. (FWRG) have gained 13.1% over the past four weeks to close the last trading session at $17.69, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.18 indicates a potential upside of 25.4%.The average comprises 11 short-term price targets ranging from a low of $17.00 to a high of $25.00, with a standard deviation of $2.18. While the lo ...

业绩总览 - 华尔街分析师预计公司季度每股收益为1.01美元，同比增长12.2% [1] - 预计季度营收为27.3亿美元，同比增长3.3% [1] - 过去30天内，市场对季度每股收益的共识预期下调了1.5% [2] 关键业务指标预测 - 预计PSE&G业务营收为22.9亿美元，同比增长7.3% [5] - 预计PSEG Power & Other业务营收为4.2688亿美元，同比下降26.9% [5] - 预计总售出及运输天然气量为4.15亿dekatherm，低于去年同期的4.36亿dekatherm [6] - 预计非固定销售天然气量为2.25亿dekatherm，低于去年同期的2.49亿dekatherm [7] - 预计固定销售天然气量为1.9亿dekatherm，高于去年同期的1.87亿dekatherm [7] 运营利润预测 - 预计Power & Other业务运营利润为5062万美元，低于去年同期的5900万美元 [8] - 预计PSE&G业务运营利润为6.7892亿美元，高于去年同期的5.82亿美元 [8] 市场表现 - 公司股价在过去一个月内下跌2.6%，同期标普500指数上涨3.8% [8]

Expand Energy (EXE) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +10.23%. A quarter ago, it was expected that this oil and gas company would post earnings of $1.14 per share when it actually produced earnings of $1.1, delivering a surprise of -3.51%.Over the last four quarters, the ...

评级升级与核心观点 - 艾默生电气被升级为Zacks Rank 2（买入）评级，这反映了其盈利预期的上升趋势[1] - 评级升级意味着市场对公司的盈利前景持积极看法，并可能对其股价产生有利影响[3] - 该评级将公司置于Zacks覆盖股票中前20%的位置，表明其近期可能跑赢市场[10] 盈利预期修正的影响 - 公司未来盈利潜力的变化与股价短期走势存在强相关性，机构投资者根据盈利预期计算公司公允价值并据此交易[4] - 盈利预期的提升意味着公司基本面的改善，投资者对这种改善趋势的认可将推动股价上涨[5] - 实证研究表明，跟踪盈利预期修正趋势进行投资决策可能带来丰厚回报[6] 艾默生电气的盈利预期 - 这家过程控制系统、阀门和分析仪器制造商预计在2025年9月结束的财年每股收益为6美元，与去年同期相比没有变化[8] - 在过去三个月中，公司的Zacks共识预期已上调0.7%[8] Zacks评级系统概述 - Zacks评级系统使用四个与盈利预期相关的因素将股票分为五类，从排名第一（强力买入）到排名第五（强力卖出）[7] - 自1988年以来，Zacks排名第一的股票平均年回报率为+25%[7] - 该系统在任何时间点对其覆盖的4000多只股票均保持“买入”和“卖出”评级的均衡比例，仅前5%的股票获得“强力买入”评级，接下来的15%获得“买入”评级[9]

Nektar Therapeutics (NKTR) closed the last trading session at $62.57, gaining 6.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $93.86 indicates a 50% upside potential.The average comprises seven short-term price targets ranging from a low of $30.00 to a high of $120.00, with a standard deviation of $29.13. While the lowest estimate indicates a decline of 52.1% from the current ...

Tamboran Resources Corporation (TBN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Indiv ...

Investors might want to bet on Tango Therapeutics, Inc. (TNGX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a ...

股价表现与分析师目标 - Tamboran Resources Corporation (TBN) 股价在过去四周上涨25.8%，收于26.61美元 [1] - 华尔街分析师给出的短期平均目标价为38美元，意味着潜在上涨空间达42.8% [1] - 五个短期目标价范围在32美元至42美元之间，标准差为3.94美元，最低和最高目标分别预示20.3%和57.8%的上涨空间 [2] 盈利预期修正 - 分析师对公司盈利前景日益乐观，一致上调每股收益（EPS）预期 [11] - 当前年度Zacks共识预期在过去一个月内上调了3.2%，且仅存在正面修正，无负面修正 [12] - TBN目前获得Zacks排名第2级（买入），表明其在基于盈利预期的4000多只股票中排名前20% [13] 分析师目标价的可靠性 - 研究表明，分析师目标价作为单一信息，误导投资者的频率高于指导作用 [7] - 分析师可能因所在机构与覆盖公司存在业务关系而设定过于乐观的目标价 [8] - 较小的目标价标准差表明分析师对股价变动方向和幅度的共识度较高，但这并非股价必定达到平均目标的保证 [9]